Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07227168 · ClinicalTrials.gov registry record · Phase 1
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
A Phase 1 study of Colorectal Cancer and Endometrial Cancer, sponsored by Sutro Biopharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 200
- Enrollment target
- 6
- Study locations
NCT07227168: Recruiting Phase 1 study of Colorectal Cancer and Endometrial Cancer, sponsored by Sutro Biopharma.
NCT07227168 is a Phase 1 study of Colorectal Cancer and Endometrial Cancer that is actively recruiting participants, run by Sutro Biopharma. The registered enrollment target is 200 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (87% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07227168, a Phase 1 study of Colorectal Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Sutro Biopharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 200 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity. * Part 1C is a dose escalation of STRO-004 combined with pembrolizumab to determine tolerability and preliminary anti-tumor activity of both drugs used together.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG STRO-004
Study Locations (6)
Texas
- NEXT Austin - Austin
- NEXT San Antonio - San Antonio
Colorado
- SCRI Denver - Denver
Florida
- SCRI FCS Sarasota - Sarasota
Massachusetts
- Mass General Cancer Center - Boston
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-11-07 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
What NCT07227168 shows while recruiting
NCT07227168 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (87% lower).
The record links to 9 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07227168 lists 6 locations in 5 states (Texas, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT07227168 about?
NCT07227168 is a clinical study titled "A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer". This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh...
What is the current status of trial NCT07227168?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 200 participants. The study started on 2025-11-07. Estimated completion is 2028-04.
What conditions does trial NCT07227168 study?
This clinical trial studies the following conditions: Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Cervical Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT07227168?
The interventions under investigation include: Pembrolizumab (DRUG), STRO-004 (DRUG).
Who is sponsoring clinical trial NCT07227168?
This trial is sponsored by Sutro Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07227168 being conducted?
This trial has 6 study locations across Colorado, Florida, Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07227168's enrollment target sits among peer trials
200 147th of 381 higher than 230 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI